Need help?

Profitable Biotechnology Company Investment Opportunity in Brussels, Belgium

Invest in a fully automated, end-to-end virtual screening platform, purpose-built for modern drug discovery.
This Business is on a Premium Plan
Established 1-5 year(s)
Employees 2 - 5
Legal Entity Limited Liability Company (LLC)
Reported Sales USD 190 thousand
Run Rate Sales USD 192 thousand
EBITDA Margin 31 %
Industries Consulting + 1 more
Locations  Brussels
Local Time 10:37 AM Europe / Brussels
Listed By Business Owner / Director
Status Active
Overall Rating
Partial Stake Sale
USD 290 thousand for 25.0% stake (Native Currency: EUR 250,000)
Reason: We’re raising €250k to extend our runway to 12 months, alongside approximately €160k of our own fund... View More
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Documents
Business Overview
- A deep-tech company based in Flanders, Belgium, was established in February, 2 years ago.
We specialize in delivering Artificial Intelligence (AI) and advanced Modeling & Simulation (M&S) solutions to the pharmaceutical industry, operating at the intersection of computational science and drug development.
- Our core offerings include a proprietary Software-as-a-Service (SaaS) platform and specialized consulting services spanning the entire drug development lifecycle—from early discovery to late-stage development—including market access, pricing, and value demonstration for novel therapies.
- We serve a diverse global client base across the pharmaceutical, biotechnology, and medical device sectors.
- Our clientele includes key players such as Deloitte Belgium, UCB Pharma, Fresenius Kabi, B. Braun, and Translucency Ltd.
- Through data-driven insights, we enable these partners to accelerate product development and optimize their market strategies.
- The company has demonstrated consistent operational growth since its inception. Our revenues reflect this trajectory, with €76,000 reported two years ago, €118,062 last year, and a projected €164,200 for this fiscal year (ending in June).
- The company maintains a stable financial position, underpinned by a net working capital of approximately €50,000, and has been awarded a €50,000 grant by VLAIO (Flanders Agency for Innovation and Entrepreneurship) to further develop our platform.
Products & Services Overview
- MVP, pre-commercial: Our AI-based, cloud-native virtual screening platform automates early discovery, from bioactivity data mining to predictive modeling and prospective compound scoring. We are raising funds to integrate the next modules—docking, generative chemistry, ADMET, and SAR-driven R-group optimization—and move toward a commercial launch.
- Revenue (Services): We provide high-value modeling and simulation services in health economics to pharmaceutical and medical device companies. Current and past clients include B. Braun, Fresenius Kabi, and Deloitte, the world’s largest consulting firm.
Assets Overview
Tangible: Physical assets include office furniture, computers, laptops and servers. These assets are not a part of this transaction.
Intangible:
- A trade mark application has been filed Proprietary - AI-drug discovery platform.
- Two lead compounds in neurodegenerative diseases such as Alzheimer's and Parkinson's.
Facilities Overview
Currently operating from home-based office within residential premises.
Capitalization Overview
Bootstrapped and founder-controlled; no external investors or debt.
Recent Activity
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
3 Investors already contacted this Business. Register below to connect now!
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses
    Frequently
    Asked
    Questions
    • Why can’t I see the business’ name or contact number? How do I contact the business?
    • What level of due diligence does SMERGERS conduct on the businesses/member?
    • How active are the business profiles listed on SMERGERS?
    • How does SMERGERS rate business profiles?
    • Do I need to pay to connect with a business?
    • Show more